Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 8,248 shares, a growth of 159.8% from the December 15th total of 3,175 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average trading volume of 4,196 shares, the short-interest ratio is currently 2.0 days. Based on an average trading volume of 4,196 shares, the short-interest ratio is currently 2.0 days. Approximately 0.4% of the shares of the stock are sold short.

Daxor Stock Performance

Daxor stock opened at $13.70 on Friday. Daxor has a 1 year low of $6.55 and a 1 year high of $14.76. The firm’s 50 day moving average price is $13.26 and its two-hundred day moving average price is $12.00.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Institutional Investors Weigh In On Daxor

An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. acquired a new position in shares of Daxor Corporation (NASDAQ:DXR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.